Literature DB >> 15735452

Interruption and discontinuation of highly active antiretroviral therapy in the multicenter AIDS cohort study.

Xiuhong Li1, Joseph B Margolick, Craig S Conover, Sheila Badri, Sharon A Riddler, Mallory D Witt, Lisa P Jacobson.   

Abstract

OBJECTIVE: Identify the determinants and consequences of interrupting and discontinuing highly active antiretroviral therapy (HAART) among a population-based cohort of HIV-infected men.
METHODS: Longitudinal analyses were applied to 2916 person-visit pairs (589 men) of continuous HAART use, 243 person-visit pairs (154 men) during which HAART was interrupted, and 151 person-visit pairs (130 men) in which HAART was discontinued by the second visit. HIV RNA increase was defined as > or =1 log10 copies/mL across the visit pairs. RESULT: : Younger age, black race, geographic location, higher HIV RNA level, depression, shorter time on HAART, lower medication adherence, and not taking a lamivudine-containing regimen predicted interrupting HAART use. Younger age, higher HIV RNA level, depression, and taking an abacavir- or lopinavir-containing regimen predicted discontinuing HAART. Among men with < or =1000 HIV RNA copies/mL, approximately 5% of those who interrupted HAART for < or =7 days and those who continued HAART had an HIV RNA increase. Men with longer interruptions and HAART discontinuers had significantly higher rates of HIV RNA increases (35.7% and 70.5%, respectively). Discontinuation and long interruptions resulted in lower CD4 cell counts.
CONCLUSIONS: Host characteristics play a role in short interruptions, whereas longer interruptions may be clinically indicated. These longer stoppages had further virologic and immunologic consequences, however.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15735452

Source DB:  PubMed          Journal:  J Acquir Immune Defic Syndr        ISSN: 1525-4135            Impact factor:   3.731


  65 in total

1.  Disparities in outcomes for African American and Latino subjects in the Flexible Initial Retrovirus Suppressive Therapies (FIRST) trial.

Authors:  Thomas P Giordano; Glenn Bartsch; Yafeng Zhang; Ellen Tedaldi; Judith Absalon; Sharon Mannheimer; Avis Thomas; Rodger D MacArthur
Journal:  AIDS Patient Care STDS       Date:  2010-05       Impact factor: 5.078

2.  CCL3 genotype and current depression increase risk of HIV-associated dementia.

Authors:  Andrew J Levine; Elyse J Singer; Janet S Sinsheimer; Charles H Hinkin; Jeanette Papp; Sugandha Dandekar; Allison Giovanelli; Paul Shapshak
Journal:  Neurobehav HIV Med       Date:  2009-11

3.  Optimization of human immunodeficiency virus treatment during incarceration: viral suppression at the prison gate.

Authors:  Jaimie P Meyer; Javier Cepeda; Johnny Wu; Robert L Trestman; Frederick L Altice; Sandra A Springer
Journal:  JAMA Intern Med       Date:  2014-05       Impact factor: 21.873

4.  Factors associated with medication refill adherence in cardiovascular-related diseases: a focus on health literacy.

Authors:  Julie A Gazmararian; Sunil Kripalani; Michael J Miller; Katharina V Echt; Junling Ren; Kimberly Rask
Journal:  J Gen Intern Med       Date:  2006-12       Impact factor: 5.128

5.  Alcohol consumption among HIV-infected women: impact on time to antiretroviral therapy and survival.

Authors:  Robyn C Neblett; Heidi E Hutton; Bryan Lau; Mary E McCaul; Richard D Moore; Geetanjali Chander
Journal:  J Womens Health (Larchmt)       Date:  2011-01-31       Impact factor: 2.681

6.  Implementation of the Medicare Part D prescription drug benefit is associated with antiretroviral therapy interruptions.

Authors:  Moupali Das-Douglas; Elise D Riley; Kathleen Ragland; David Guzman; Richard Clark; Margot B Kushel; David R Bangsberg
Journal:  AIDS Behav       Date:  2008-05-16

7.  Ten-year trends in antiretroviral therapy persistence among US Medicaid beneficiaries.

Authors:  Bora Youn; Theresa I Shireman; Yoojin Lee; Omar Galárraga; Aadia I Rana; Amy C Justice; Ira B Wilson
Journal:  AIDS       Date:  2017-07-31       Impact factor: 4.177

8.  Discontinuation of antiretroviral therapy among adults receiving HIV care in the United States.

Authors:  Alison J Hughes; Christine L Mattson; Susan Scheer; Linda Beer; Jacek Skarbinski
Journal:  J Acquir Immune Defic Syndr       Date:  2014-05-01       Impact factor: 3.731

9.  Race/ethnicity and risk of AIDS and death among HIV-infected patients with access to care.

Authors:  Michael J Silverberg; Wendy Leyden; Charles P Quesenberry; Michael A Horberg
Journal:  J Gen Intern Med       Date:  2009-07-16       Impact factor: 5.128

10.  HAART receipt and viral suppression among HIV-infected patients with co-occurring mental illness and illicit drug use.

Authors:  Geetanjali Chander; Seth Himelhoch; John A Fleishman; James Hellinger; Paul Gaist; Richard D Moore; Kelly A Gebo
Journal:  AIDS Care       Date:  2009-05
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.